Successful Targeting of BRAF V600E Mutation With Vemurafenib in a Treatment-Resistant Extragonadal Nonseminomatous Germ-Cell Tumor

Meintker L, Haller F, Tögel L, Schmidt D, Waibel H, Hartmann A, Mackensen A, Meidenbauer N (2020)

Publication Type: Journal article

Publication year: 2020

Journal

JCO Precision Oncology American Society of Clinical Oncology

Pages Range: 233-238

Issue: 4

DOI: 10.1200/PO.19.00377

Authors with CRIS profile

Lisa Meintker Department of Medicine 5 – Haematology and Oncology Florian Haller Professur für Diagnostische Molekularpathologie Lars Tögel Lehrstuhl für Experimentelle Medizin mit dem Schwerpunkt Molekulare Pathogeneseforschung Daniela Schmidt Medizinische Fakultät Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Andreas Mackensen Lehrstuhl für Innere Medizin V Norbert Meidenbauer Department of Medicine 5 – Haematology and Oncology

How to cite

APA:

Meintker, L., Haller, F., Tögel, L., Schmidt, D., Waibel, H., Hartmann, A.,... Meidenbauer, N. (2020). Successful Targeting of BRAF V600E Mutation With Vemurafenib in a Treatment-Resistant Extragonadal Nonseminomatous Germ-Cell Tumor. JCO Precision Oncology, 233-238. https://doi.org/10.1200/PO.19.00377

MLA:

Meintker, Lisa, et al. "Successful Targeting of BRAF V600E Mutation With Vemurafenib in a Treatment-Resistant Extragonadal Nonseminomatous Germ-Cell Tumor." JCO Precision Oncology (2020): 233-238.

BibTeX: Download